“…Seven days that positioned Open Orphan as the world leader in the testing of vaccines and antivirals using human challenge clinical trials…”
Within one week Open Orphan announced two international deals that gave unequivocal proof about the company’s growth as a specialist CRO pharmaceutical services company.
A contract with US biotech company Codagenix to conduct a first in human trial evaluating safety and immunogenicity of a single-dose, intranasal COVID-19 vaccine candidate; and a contract with Japan’s Carna Bioscience for a first in human clinical pharmacology trial.
The Carna contract alone is expected to deliver significant revenue for Open Orphan’s subsidiary Venn Life Sciences over the next twelve months.
Open Orphan describes itself as the world leader in the testing of vaccines and antivirals using human challenge clinical trials, and since listing on AIM in June 2019 the share price has doubled.
Listen to Chairman Cathal Friel explain to Sarah Lowther why fund manager Neil Woodford has transformed his and the lives of Open Orphan shareholders, and why the combined legacy will assist the world for generations to come.
From his bolthole in Donegal, Cathal talks to Proactive UK’s Andrew Scott about US biotech Codagenix commissioning Open Orphan’s hVIVO arm to carry out a first-in-human trial of a nasal vaccine for coronavirus.
Click here to read Open Orphan’s June 2020 Investor presentation
The author was remunerated but does not hold shares in the company
